Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
BSF 208075 · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| BSF 208075 | DRUG | - |
--Disease Characteristics-- * Current diagnosis of either PPH or PAH secondary to the scleroderma spectrum of disease (e.g., mixed connective tissue disease, systemic lupus erythematosus, systemic sclerosis, or overlap syndrome), anorexigen use, or human immunodeficiency virus (HIV) infection at th...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| United Therapeutics Corporation | UTHR | 5 | PHASE3 | Ralinepag |
| Merck & Co., Inc. | MRK | 6 | PHASE3 | Riociguat |
| Insmed Incorporated | INSM | 4 | PHASE3 | Treprostinil Palmitil |
| Johnson & Johnson | JNJ | 4 | PHASE3 | Selexipag |
| Liquidia Corporation | LQDA | 4 | PHASE3 | L606 |
| Tenax Therapeutics, Inc. | TENX | 3 | PHASE3 | TNX-103 |
| Inhibikase Therapeutics, Inc. | IKT | 1 | PHASE3 | IKT-001 |
| Gossamer Bio, Inc. | GOSS | 2 | PHASE3 | Seralutinib |
| Regeneron Pharmaceuticals, Inc. | REGN | 1 | PHASE2 | REGN13335 |
| Pfizer Inc. | PFE | 1 | PHASE2 | PF-07868489 |
| Tectonic Therapeutic Inc | TECX | 1 | PHASE2 | TX000045- Dose A, TX000045- Dose B |
| Abbott Laboratories | ABT | 1 | N/A | Undisclosed |
BSF 208075 is an investigational small molecule being studied for the treatment of pulmonary hypertension, specifically pulmonary arterial hypertension. It is being developed by Gilead Sciences, Inc. (NASDAQ: GILD) and is currently in Phase 2 clinical development.
BSF 208075 is a small molecule being developed for pulmonary hypertension. Its specific molecular target has not been disclosed in available clinical trial information. The drug is being evaluated for its effects on exercise capacity in patients with pulmonary arterial hypertension.
BSF 208075 is being developed by Gilead Sciences, Inc., a biopharmaceutical company traded on NASDAQ under the ticker symbol GILD. The drug is currently in Phase 2 clinical development for the treatment of pulmonary hypertension.
BSF 208075 is in Phase 2 clinical development. It is an investigational drug and has not been approved by regulatory authorities. A Phase 2 clinical trial evaluating the drug in patients with pulmonary arterial hypertension has been completed.
BSF 208075 has been studied in one completed Phase 2 clinical trial, identified as NCT00046319. This trial evaluated exercise capacity in 60 patients with pulmonary arterial hypertension and was conducted in the United States, Australia, Belgium, France, Germany, and Italy.
BSF 208075 is the investigational name for the drug also known as ambrisentan. It is being developed by Gilead Sciences for the treatment of pulmonary arterial hypertension. The drug is a small molecule and has completed a Phase 2 clinical trial.